Last-Minute Cancellation Of Advisory Panel Meeting Throws Future of Luveniq Into Doubt
This article was originally published in The Pink Sheet Daily
Executive Summary
"Several outstanding issues" forced FDA to cancel the meeting, the agency said.
You may also be interested in...
Advisory Panel For Bristol's Yervoy Is Called Off, Which May Bode Well
After extending the review, FDA says it no longer needs ODAC's advice on the second-line melanoma treatment, which looks like a good sign for approval.
Advisory Panel For Bristol's Yervoy Is Called Off, Which May Bode Well
After extending the review, FDA says it no longer needs ODAC's advice on the second-line melanoma treatment, which looks like a good sign for approval.
FDA Says Lux's Uveitis Treatment Luveniq Needs Another Clinical Trial
Lux Biosciences will have to do another clinical trial - on top of three already completed Phase III studies - for FDA to consider approving its uveitis treatment Luveniq (voclosporin), the agency said in a "complete response" letter announced Aug. 4